Patients with MDS and AML, who receive treatment with azacitidine, will be recruited through the Department of Hematology at Herlev Hospital. Since all patients are followed in an outpatient setting, for around six months prior to inclusion while receiving azacitidine treatment, possible candidates can be identified early and properly informed before a consent form needs to be signed.